![]() ![]() "I'm happy to welcome Novamind as a strategic investor in Bionomics," said Dr. Robison has led over 100 clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD. Reid Robison, is currently contracted for seven clinical trials with various sponsors, including leading pharmaceutical companies. With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences.Ĭedar Clinical Research, led by Novamind's Chief Medical Officer, Dr. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD). BNC210 has received Fast Track Designation from the U.S. #Novamind canada trial#In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210. (CSE:NM) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the "Strategic Investment"), in Bionomics Limited ("Bionomics") (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders. TORONTO, ON / ACCESSWIRE / Febru/ Novamind Inc. Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |